Omada Health rises as weight loss program shows strong results in year-long study

Shares of virtual chronic care provider Omada Health OMDA.O rise 2% to $16.90 premarket

Co says members in its program lost 18.4% body weight on GLP-1 drugs vs 11.9% in other studies

Average weight loss for all participants was 16.3%, nearly double similar research, co says

67% stayed on medication for a year vs 47% to 49% in other studies, OMDA adds

Program combines drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide with coaching and lifestyle advice, co says

As of last close, stock up ~5% over the past year